Hospital
Columbia Hospital Corporation of South Broward
Columbia Hospital Corporation of South Broward was paid $9.83M by Medicaid between Jan 2018 and Dec 2024, across 153 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoCOLUMBIA HOSPITAL CORPORATION OF SOUTH BROWARD
PLANTATION, FL 33324
PLANTATION, FL 33324
33aNPI1063466589assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.83M
24GClaims500,914
24DCodes billed153
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#53 of 163
Median peer was paid$4.77M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,338 | $258K | |
| 2019 | 74,809 | $553K | |
| 2020 | 47,772 | $462K | |
| 2021 | 71,738 | $1.47M | |
| 2022 | 134,395 | $3.53M | |
| 2023 | 101,664 | $2.30M | |
| 2024incomplete | 42,198 | $1.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 43,529 | 39,182 | $2.87M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 29,340 | 25,208 | $1.35M |
| 80053 | Comprehensive metabolic panel | 5.6% | 14,281 | 11,615 | $551K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 5,413 | 4,352 | $463K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 5,872 | 5,495 | $450K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.4% | 2,480 | 2,121 | $435K |
| 87070 | 3.9% | 5,319 | 5,126 | $383K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 2,111 | 1,862 | $324K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 6,613 | 5,319 | $322K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.0% | 15,190 | 11,964 | $297K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.4% | 2,916 | 2,685 | $241K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 667 | 597 | $140K |
141 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,551 | $112K |
| 80047 | 1.1% | 4,390 | $106K | |
| 81025 | 1.0% | 7,386 | $101K | |
| G0378 | Hospital observation service, per hour | 1.0% | 7,671 | $101K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,206 | $79K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,936 | $76K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,173 | $72K |
| 80076 | <1% | 6,308 | $72K | |
| 84702 | <1% | 2,338 | $63K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,413 | $61K |
| 74022 | <1% | 675 | $60K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,917 | $59K |
| 87040 | <1% | 2,801 | $57K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 530 | $57K |
| 73630 | <1% | 1,182 | $52K | |
| 84484 | <1% | 12,690 | $50K | |
| 74018 | <1% | 811 | $49K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 460 | $43K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 11,067 | $40K |
| 73130 | <1% | 725 | $39K | |
| 87275 | <1% | 13,640 | $35K | |
| 73564 | <1% | 929 | $35K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,253 | $34K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,100 | $29K |
| 93971 | <1% | 372 | $29K | |
| 73030 | <1% | 684 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 495 | $26K |
| A9270 | Non-covered item or service | <1% | 12,680 | $25K |
| 73110 | <1% | 359 | $23K | |
| 72100 | <1% | 560 | $21K | |
| 85027 | <1% | 36,844 | $21K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,902 | $19K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 805 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 556 | $18K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,774 | $16K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 539 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,676 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,839 | $16K |
| 86850 | <1% | 1,309 | $14K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 931 | $14K |
| 73610 | <1% | 865 | $13K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,112 | $10K |
| 81001 | <1% | 7,482 | $9K | |
| 81003 | <1% | 5,291 | $9K | |
| 85610 | <1% | 9,185 | $9K | |
| 85730 | <1% | 8,853 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,906 | $8K |
| 70486 | <1% | 109 | $8K | |
| 93976 | <1% | 47 | $8K | |
| 93970 | <1% | 68 | $8K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 508 | $8K |
| 87276 | <1% | 13,636 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,956 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,614 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,481 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,688 | $5K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,751 | $4K |
| 72131 | <1% | 91 | $4K | |
| 83690 | <1% | 10,204 | $4K | |
| 84703 | <1% | 7,451 | $4K | |
| 73080 | <1% | 62 | $3K | |
| 76801 | <1% | 1,340 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,520 | $3K |
| 73502 | <1% | 135 | $3K | |
| 83880 | <1% | 4,222 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,392 | $2K |
| 82040 | <1% | 969 | $2K | |
| 84450 | <1% | 967 | $2K | |
| 84460 | <1% | 968 | $2K | |
| 84075 | <1% | 969 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,588 | $2K |
| 84155 | <1% | 966 | $2K | |
| 82247 | <1% | 971 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,853 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 398 | $2K |
| 73140 | <1% | 15 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,558 | $2K |
| 71250 | <1% | 14 | $2K | |
| 10060 | <1% | 93 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 237 | $1K |
| 12001 | <1% | 30 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,513 | $1K |
| 86900 | <1% | 2,303 | $1K | |
| 73590 | <1% | 19 | $949.16 | |
| 73562 | <1% | 15 | $870.57 | |
| 72040 | <1% | 12 | $823.92 | |
| 82550 | <1% | 1,262 | $805.26 | |
| 87807 | <1% | 1,884 | $787.77 | |
| 71101 | <1% | 13 | $709.98 | |
| 83605 | <1% | 2,774 | $706.86 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 29 | $685.93 |
| 82248 | <1% | 1,564 | $656.50 | |
| 85379 | <1% | 1,482 | $558.57 | |
| 86901 | <1% | 2,317 | $548.29 | |
| J1815 | Injection, insulin, per 5 units | <1% | 562 | $547.80 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 444 | $546.89 |
| 90714 | <1% | 331 | $545.01 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 142 | $542.61 |
| 83735 | <1% | 2,124 | $541.21 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 648 | $520.50 |
| 72070 | <1% | 26 | $467.54 | |
| 12011 | <1% | 12 | $462.75 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,594 | $462.19 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,411 | $429.49 |
| 73090 | <1% | 14 | $421.44 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 905 | $382.46 |
| 87186 | <1% | 40 | $351.18 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 378 | $347.15 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 510 | $284.11 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,325 | $276.95 |
| J3490 | Unclassified drugs | <1% | 293 | $172.68 |
| 97162 | <1% | 43 | $153.72 | |
| 80061 | Lipid panel | <1% | 542 | $138.30 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 255 | $116.92 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,727 | $105.36 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 583 | $105.36 |
| 82150 | <1% | 141 | $89.56 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 354 | $60.97 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 366 | $52.68 |
| 86140 | <1% | 700 | $50.23 | |
| 82553 | <1% | 218 | $35.48 | |
| 84100 | <1% | 184 | $6.75 | |
| 85651 | <1% | 471 | $6.60 | |
| 87081 | <1% | 17 | $5.40 | |
| 85007 | <1% | 422 | $4.50 | |
| J2704 | Injection, propofol, 10 mg | 0% | 152 | $0.00 |
| C1769 | Guide wire | 0% | 48 | $0.00 |
| 87205 | 0% | 91 | $0.00 | |
| 96376 | 0% | 318 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 70 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 204 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 59 | $0.00 |
| 82077 | 0% | 15 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 19 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 32 | $0.00 |
| 82805 | 0% | 53 | $0.00 | |
| 82010 | 0% | 32 | $0.00 | |
| 36600 | 0% | 37 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 15 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 14 | $0.00 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUGHES, MATT (CFO)